Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada

BACKGROUND: In Canada, reimbursement recommendations on drugs for common and rare diseases are overseen by the Canadian Agency for Drugs and Technologies in Health (CADTH) and made through the pan-Canadian Oncology Drug Review (pCODR) and the Common Drug Review (CDR). While the agency specifies info...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagase, Fernanda Naomi Inagaki, Stafinski, Tania, Sun, Jian, Jhangri, Gian, Menon, Devidas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555917/
https://www.ncbi.nlm.nih.gov/pubmed/31174574
http://dx.doi.org/10.1186/s13023-019-1104-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555917/
https://www.ncbi.nlm.nih.gov/pubmed/31174574
http://dx.doi.org/10.1186/s13023-019-1104-7

Ejemplares similares